ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1137

The Incidence of BK Viremia Among Recipients Who Received Kidney Transplants (KT) from Hepatitis C-Infected and Uninfected Donors

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Yazawa, Masahiko, University of Tennessee Health Science Center, Memphis, United States
  • Cseprekál, Orsolya, Semmelweis University, Budapest, Hungary
  • Talwar, Manish, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Balaraman, Vasanthi, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Eason, James D., University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Molnar, Miklos Zsolt, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Group or Team Name

  • METEOR (MEthodist Transplant EpidemiOlogy Research) Group
Background

Our previous data showed KT from hepatitis C virus(HCV) infected donor to non-infected recipients might be associated with higher incidence of BK viremia.

Methods

One hundred and ninety-two deceased KT recipients (74 HCV infected(D+/R-) and 55 HCV negative (D-/R-) donor) to HCV negative recipients were included. Outcome was defined as time to incidence BK viremia which 1)was detectable in blood specimen by PCR (BK viremia;n=21), 2)was greater than 10,000 copies/mL (high BK viremia;n=9). We performed time to event analysis from KT to 120 days after KT with unadjusted and thymoglobulin dose adjusted Cox regression model.

Results

The mean age at KT was 52±11 years old and 80% were African-American. Table shows the baseline characteristics of HCV D+/R- and D-/R- groups. The median number of the highest viral copies was tended to be 5-fold higher in HCV D+/R- group (median:19,632; interquartile range (IQR):2,329-303,823 copies/mL) than D-/R- group (median:4,356; IQR:2,931-15,219 copies/mL,p=0.45). Figure shows the probability of the (high) BK viremia over the follow-up time. Compared to D-/R-, HCV D+/R- group reported similar probability of BK viremia in unadjusted (Hazard Ratio(HR):1.32, 95% Confidence Interval(CI):0.54-3.19) and adjusted (HR:1.28, 95%CI:0.52-3.13) model, a trend for higher risk for high BK viremia unadjusted (HR:2.87, 95%CI:0.60-13.8) and adjusted (HR:2.68, 95% CI:0.56-12.9) Cox regression model.

Conclusion

HCV D+/R- KT was not associated with higher incidence of BK viremia and showed trend for higher incidence of BK viremia.

Figure 1